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Platelet Aspirin
Resistance Detection and Validation
In a recent paper in the Journal, Tantry et al. (1) concluded that the
occurrence of aspirin resistance in published reports is overesti-
mated, implying that this was due to the use of assays that did not
measure cyclooxygenase-1 (COX-1) activity. Although these in-
vestigators reported an incidence of aspirin resistance of 0.4%,
several reviews estimate, based on a large number of studies, that
the incidence of aspirin resistance is between 5% and 45% (2).
Moreover, the Tantry et al. (1) study has serious limitations that
call into question the generalizability of their findings.
First, their research population consisted primarily of patients
with stable angina. A number of studies have demonstrated that
aspirin resistance is more prevalent in patients with acute coronary
syndromes than in patients with stable angina (2), and thus their
study may underestimate the prevalence of aspirin resistance in
those at greatest risk. Second, by employing a dose of 325 mg of
aspirin, their data may not be applicable to the vast majority of
patients who currently are treated with 81 mg per day. Third,
because their definition of aspirin resistance has not been validated
against clinical outcomes, it is arbitrary and thus must be viewed as
speculative. Fourth, the thrombelastograph (TEG) assay they use
has not undergone extensive critical evaluation.
Tantry et al. (1) also do not accurately portray the VerifyNow–
ASA System (Ultegra System, Accumetrics, San Diego, California),
which employs arachidonic acid (AA) as the agonist and thus does
assess COX-1 activity. When compared to light transmission aggre-
gometry (LTA) using AA, the VerifyNow assay demonstrated
91.4% sensitivity and 100% specificity (VerifyNow–ASA package
insert). Although a previous generation of the VerifyNow device
did use propyl gallate (PG) as the agonist, Schwartz et al. (3)
demonstrated that PG detects aspirin-induced inhibition of plate-
lets with 100% sensitivity and differentiates the degree of aspirin-
induced inhibition of platelet function produced by single doses of
81 mg and 325 mg, and hence is a specific activator of the
aspirin-inhibited COX-1 pathway. Most importantly, results of
the VerifyNow assay have been correlated to clinical outcome in
several studies, including one published in JACC (4–6).
Several studies, including a recent one by Lee et al. (7) with
VerifyNow, have demonstrated that aspirin resistance decreases
with increasing dose of aspirin, from 81 mg to 325 mg. Maree
et al. (8) also demonstrated using AA-induced LTA as well as
serum thromboxane measurements, the gold standard, that “many
patients who are prescribed low-dose aspirin (81 mg) have persis-
tent uninhibited platelet COX activity.” Further, Serebruany et al.
(9) have shown that major bleeding increases from 1% to 3% as
aspirin dose is increased from 81 mg to 325 mg Thus, there is a
graded effect in both safety and efficacy of aspirin that should be
considered.
Noncompliance and drug interactions with nonsteroidal anti-
inflammatory drugs (e.g., ibuprofen) contribute to the reported
incidence of “aspirin resistance” in the real world of clinical
practice, and many investigators, including Cotter et al. (10),
conclude that “nonadherence is a significant mediator of poor
outcome . . . and it is important to evaluate whether or not patients
are taking their medications in clinical settings.” Thus, assays that
ensure an antiplatelet effect may have great clinical value even in
patient populations in whom, as reported by Tantry et al. (1),
biochemical aspirin resistance is uncommon.
As stated by Schneider (11) in an accompanying editorial, initial
techniques used to assess the effect of glycoprotein IIb/IIIa
inhibitors on platelet function were inadequate. The original
VerifyNow IIb/IIIa assay was used in the AU-Assessing Ultegra
(GOLD) study (12), which served to definitively establish the
correlation between platelet inhibition and clinical outcomes.
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We appreciate Dr. Hillman’s interest in our study assessing
cyclooxygenase (COX)-1 inhibition by stimulation of platelets
with arachidonic acid (AA) in platelet-rich plasma and whole
blood. We address his comments:
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